– Clinical supply agreement with AstraZeneca (AZN) for global Phase 1b/2 study to evaluate the safety and early efficacy of etakafusp alfa (AB248) in combination with rilvegostomig as a first-line ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback